On June 13, 2022 NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, reported that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA (Press release, NeoImmuneTech, JUN 13, 2022, View Source [SID1234615950]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sam Zhang, Ph.D., MBA, NeoImmuneTech Chief Business Officer said: "One week after NeoImmuneTech presented new promising data at ASCO (Free ASCO Whitepaper) 2022 congress, the BIO International Convention is a perfect opportunity to remind the scientific and industry community about the momentum of our broad development program with NT-I7, our long-acting human IL-7, in combination with checkpoint inhibitors and CAR-Ts".
The details of the company’s presentation are as follows:
BIO International Convention
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.